The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...
Rigel Pharmaceuticals (RIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
Monday - Friday, 2:00 - 3:00 PM ET In this article It's been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for hematology ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with ...
Rigel Pharma has 2 FDA-approved drugs: Tavalisse for chronic immune thrombocytopenia (ITP) and Rezlidhia for relapsed or refractory AML with susceptible IDH1 mutation. In Q4 2022, Tavalisse revenue ...
Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Second Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session ...
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) shares are on the move Wednesday after the company reported fourth-quarter results well above analyst expectations. What Happened: Rigel reported fourth-quarter ...
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif., Oct. 8, 2025 /PRNewswire/ -- Rigel ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results